crystalline form 4 - ((r) -2 - {6 - ((s) -3-methoxy-pyrrolidin-1-yl) -2-phenyl-pyrimidin-4-carbonyl -amino} acid butyl ester hydrochloride -3-phosphono-propionyl) -piperazine-1-carboxylic acid process for preparing 4 - ((r) -2 - {6 - ((s) -3-methoxy-pyrrolidin-1-butyl ester) hydrochloride yl) -2-phenyl-pyrimidine-4-carbonyl -amino} -3-phosphono-propionyl) -piperazine-1-carboxylic acid pharmaceutical composition and 4 - ((r) -2 - {6 butyl ester - ((s) -3-Methoxy-pyrrolidin-1-yl) -2-phenyl-pyrimidin-4-carbonyl -amino} -3-phosphono-propionyl) -piperazine-1-carboxylic acid.

摘要

The invention relates to crystalline forms of 4 - ((r) -2 - {[6 - ((s) -3-methoxy-pyrrolidin-1-yl) -2-phenyl-pyrimidine-2-butyl ester hydrochloride Carbonyl] amino} -3-phosphono-propionyl) piperazine-1-carboxylic, processes for their preparation, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms and their use as a medicament, especially as a p2y12 receptor antagonist.